利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

119 条记录 (耗时 0.046 秒)

    METHOD FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
    81.
    发明申请
    METHOD FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA 有权
    治疗高脂血症的方法

    公开(公告)号：US20150306060A1

    公开(公告)日：2015-10-29

    申请号：US14637081

    申请日：2015-03-03

    申请人： Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Anju Majeed ,  Sarang Bani ,  Anjali Pandey

    发明人： Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Anju Majeed ,  Sarang Bani ,  Anjali Pandey

    IPC分类号： A61K31/25

    CPC分类号： A61K31/25 ,  A61K31/215

    摘要： Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides.

    摘要翻译： 公开了哺乳动物高胆固醇血症的治疗管理方法。 更具体地说，本发明涉及一种降低哺乳动物血液中高水平循环胆固醇（高胆固醇血症）的方法，所述方法包括向所述哺乳动物施用治疗有效量的贻贝A以产生（i ）降低总胆固醇含量; （ii）降低低密度脂蛋白（LDL）和极低密度脂蛋白（VLDL）的浓度; （iii）增加高密度脂蛋白（HDL）的浓度和（iv）降低血清甘油三酸酯的浓度。

    Anti-obesity Potential of Calebin A
    85.
    发明申请
    Anti-obesity Potential of Calebin A 有权
    Calebin的抗肥胖潜力A

    公开(公告)号：US20130012579A1

    公开(公告)日：2013-01-10

    申请号：US13347071

    申请日：2012-01-10

    申请人： Muhammed Majeed ,  Anjali Pandey

    发明人： Muhammed Majeed ,  Anjali Pandey

    IPC分类号： A61K31/235 ,  A61P3/04 ,  C12N5/077

    CPC分类号： A61K31/235 ,  C12N5/0653 ,  C12N2500/76

    摘要： The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-α), Interleukin-6 (IL-6) and Interleukin-1 (IL-1β).

    摘要翻译： 本发明公开了Calebin A在肥胖管理中抑制脂肪形成及其应用的潜力。 本发明阐明了Calebin A有利地调节与肥胖相关的生化标志物的潜力。 Calebin A的显着生物学特性包括抑制瘦素生成，增加脂联素表达和抑制局部（脂肪细胞）和由促炎细胞因子肿瘤坏死因子（TNF-α），白细胞介素-6（IL-6）和白介素-1 （IL-1＆bgr））。

    PROTEIN KINASE INHIBITORS
    88.
    发明申请
    PROTEIN KINASE INHIBITORS 有权
    蛋白激酶抑制剂

    公开(公告)号：US20090054425A1

    公开(公告)日：2009-02-26

    申请号：US12192034

    申请日：2008-08-14

    申请人： Yonghong Song ,  Qing Xu ,  Anjali Pandey

    发明人： Yonghong Song ,  Qing Xu ,  Anjali Pandey

    IPC分类号： A61K31/496 ,  C07D487/04 ,  A61K31/538 ,  A61P7/00 ,  A61P9/00 ,  A61P29/00 ,  A61P35/02 ,  C07D413/14

    CPC分类号： C07D487/04

    摘要： Compounds, particularly compounds having spleen tyrosine kinase (Syk) inhibition activity, having the following structure: or a pharmaceutically acceptable salt thereof, wherein R1 is structure (a), (b), (c) or (d): and Ra, Rb, Rc, R2, R3, R4, R5, R6 and R7 are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed, as well as uses of the same to treat a condition or disorder mediated by a Syk and/or JAK kinase.

    摘要翻译： 具有以下结构的化合物，特别是具有脾酪氨酸激酶（Syk）抑制活性的化合物或其药学上可接受的盐，其中R 1是结构（a），（b），（c）或（d）：和Ra，Rb ，Rc，R2，R3，R4，R5，R6和R7如本文所定义。 还公开了与其制备和使用相关的方法以及含有该组合物的药物组合物，以及其用于治疗由Syk和/或JAK激酶介导的病症或病症的用途。

    Compositions and methods for inhibiting TGF-Beta
    89.
    发明申请
    Compositions and methods for inhibiting TGF-Beta 失效
    用于抑制TGF-β的组合物和方法

    公开(公告)号：US20070142408A1

    公开(公告)日：2007-06-21

    申请号：US11653679

    申请日：2007-01-16

    申请人： Robert Scarborough ,  Anjali Pandey ,  Meenakshi Venkatraman

    发明人： Robert Scarborough ,  Anjali Pandey ,  Meenakshi Venkatraman

    IPC分类号： A61K31/517 ,  A61K31/4745 ,  C07D471/02

    CPC分类号： C07D471/04

    摘要： This invention provides compounds that are useful for treating patients having a TGF-β-mediated disease, particularly an ALK5-mediated disease. The compounds are represented by formula I: wherein: a-b is CH2CH2, CH2CH2CH2, CH═CH, CH═N, or N═CH; Z is N or C—F; and G is C1-6 aliphatic or a phenyl, naphthyl, or 5-6 membered heteroaryl ring.

    摘要翻译： 本发明提供可用于治疗患有TGF-β介导的疾病，特别是ALK5介导的疾病的患者的化合物。 化合物由式I表示：其中：ab是CH 2 CH 2 CH 2，CH 2 CH 2 CH 2 CH 2，CH-CH，CH-N或N-CH; Z是N或C-F; 和G为C 1-6脂族基或苯基，萘基或5-6元杂芳基环。